Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19

Coronavirus disease (COVID)-19 is the leading global health threat to date caused by a severe acute respiratory syndrome coronavirus (SARS-CoV-2). Recent clinical trials reported that the use of Bruton’s tyrosine kinase (BTK) inhibitors to treat COVID-19 patients could reduce dyspnea and hypoxia, th...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Int J Mol Sci
Päätekijät: Kaliamurthi, Satyavani, Selvaraj, Gurudeeban, Selvaraj, Chandrabose, Singh, Sanjeev Kumar, Wei, Dong-Qing, Peslherbe, Gilles H.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: MDPI 2021
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8267665/
https://ncbi.nlm.nih.gov/pubmed/34209188
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms22137071
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia